The case for the format.
The chemistry in a rapid test already works. What fails is everything built around it: the plastic cassette, the cold chain, and a supply line that rarely reaches where testing is needed most. Dianovo changes the format. CENTiV makes diagnostics on a continuous cellulose roll instead of one molded cassette at a time, so a single reader runs the whole menu and each new test is new chemistry on the same hardware. The model is reader-plus-roll: one durable reader, recurring sealed rolls.
Dianovo has closed its pre-seed round and is now raising a seed round.
A large, recurring market carrying decades of built-in overhead.
2 billion+
Tests produced every year
More than two billion lateral-flow tests are produced annually.
USD 7.35 billion
HIV, HBV and HCV test-kit market (2025)
Syphilis is a fourth marker on the CENTiV panel and is not counted in this figure.
USD 10 billion+
Wider lateral-flow market (2025)
Projected to reach nearly USD 17 billion by 2033.
That volume ships with tens of thousands of metric tons of plastic and packaging that do nothing for the test, alongside a cold chain that dominates logistics in the markets that need testing most. The overhead is the opportunity: a reader-plus-roll platform built to remove it.
A lower all-in cost per test.
Counting the price of the test plus transport and waste handling, By our own modeling, CENTiV can lower the cost of testing by roughly a third to 68 percent, depending on the procurement scenario. The largest savings come where it ships with no cold chain and far less clinical waste. Modeled across EU, LMIC, and South African procurement scenarios.
All-in cost per test
A third to 68% lower
One reader for the whole menu.
Every CENTiV test is new chemistry on the same reader. That makes multiplex panels practical without a separate device for each one, including combinations the single-cassette format leaves undone because a dedicated cassette is not worth tooling.
Example: the WHO triple panel
In July 2025 the World Health Organization prequalified the first triple diagnostic test for HIV, hepatitis B, and syphilis, the combination its triple elimination initiative calls for. The prequalified product is three separate rapid tests bundled in one box. WHO estimated about 661,000 congenital syphilis cases in 2016, including 355,000 adverse birth outcomes. CENTiV is designed to deliver panels like this on a single strip.
The timing is structural, not incidental.
The last unsolved part
The format is the last part of the rapid test that has not been re-engineered in about forty years. The chemistry works. The cassette around it does not.
Manufacturing is mature
Roll-to-roll is an established industrial process, so reaching volume draws on existing capability rather than a custom scale-up.
EU-origin advantage
Commission Implementing Regulation (EU) 2025/1197 excludes Chinese suppliers from EU public medical-device tenders valued at EUR 5 million or above, in force from June 30, 2025, for five years. It also caps Chinese-origin content at 50 percent of contract value. CENTiV is EU-origin, with component supply auditable for that cap.
The pressure is moving to the buyers.
Public buyers are being told to weigh waste and carbon, not only price. That shift favors a lower-waste device. Note that the EU Single-Use Plastics Directive exempts medical devices, so the leverage here is procurement and carbon rules, not a plastic ban.
NHS carbon procurement
The NHS scores suppliers on carbon. Per-product carbon footprinting is required from 2028, and contracting becomes progress-gated from 2030, so lower-footprint diagnostics gain an advantage.
NHS single-use phase-out
The UK Design for Life roadmap, published in 2024, commits the health system to move away from avoidable single-use medtech toward a circular model by 2045.
Nordic and French tenders
Norway has required environmental criteria to carry at least 30 percent of the award weighting on above-threshold public tenders since 2024. France requires sustainable-procurement schemes for large public buyers, including hospitals.
EU lifecycle-cost tenders
EU public procurement rules let buyers weigh lifecycle cost and environmental impact in tender scoring, across about EUR 1.8 trillion of annual public spend.
The packaging clock
The EU Packaging and Packaging Waste Regulation took effect in 2025. In-vitro diagnostic packaging receives reduced-target carve-outs, not a blanket exemption, which puts the incumbent cassette on a regulatory timeline.
Funders are diversifying supply
The Global Fund, PEPFAR, and Unitaid opened a supply-diversification pathway in 2023 that named HIV rapid tests as its first category. HIV is one of the three markers on the CENTiV antenatal panel.
The bigger challenge is calibration, not the underlying science.
CENTiV is at an early technology-readiness stage and has not yet completed laboratory validation. That stage carries less scientific risk than it may appear to. The detection chemistry is established lateral-flow immunoassay, and the innovation is the format and the manufacturing, not the underlying assay. The open question is not whether lateral-flow detection works. It is whether it performs as intended on a continuous roll.
Established chemistry
Lateral-flow immunoassay is a mature detection method, documented across decades of literature and regulated products. CENTiV applies it. It does not reinvent it.
Known materials and methods
The substrate, reagents, and optical readout rely on well-characterized materials and documented methods, not unproven science.
Calibration, not invention
The work ahead is engineering, not discovery: calibrating the assay to specification on the roll format and integrating it with the reader.
What is already in place.
Intellectual property
Two patents pending under Swedish priority filings, covering the platform and a result-privacy mechanism.
Named collaborators
A network of research, clinical, regulatory, and commercial partners across Europe and South Africa.
Non-dilutive funding
Grant funding pursued in parallel with the seed round.
Ideon Science Park
Hosted in the Medicon Valley life-science cluster, adjacent to Lund University.
Quality management
Under implementation in alignment with ISO 13485 and IVDR requirements. Not a certification claim.
A staged path
The system is defined today, with a staged path to prototype, clinical feasibility, and certification.
Healthcare is the entry point. The same line runs adjacent markets.
These are expansion markets, not current targets. Healthcare is the sole near-term focus. Food safety, veterinary, biodefense, and environmental testing run on the same manufacturing platform, each a separate market the same reader-plus-roll model can address later.
Food safety
USD 19.66 to 31.22 billion
Rapid food safety testing, 2025 to 2030.
Veterinary
USD 10.71 to 19.00 billion
Veterinary diagnostics, 2024 to 2030.
Biodefense
USD 16.03 to 25.06 billion
Global biodefense, 2023 to 2032.
Environmental
USD 10.90 to 17.00 billion
Environmental testing, 2025 to 2032.
Let's talk.
We closed our pre-seed round and are now raising our seed round to take CENTiV from system definition to an integrated prototype and analytical validation. Tell us about your fund and the stages you invest at, and we will send the current deck and set up a call.